Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Absci Corporation (Nasdaq: ABSI) announced it will release its Q3 2021 financial results on November 9, 2021. The company will host a webcast conference call at 5:30 AM PT / 8:30 AM ET to discuss the results. Absci focuses on drug discovery through deep learning AI and synthetic biology to enhance protein therapeutics. Their Integrated Drug Creation™ Platform allows identification of new drug targets and optimal biotherapeutic candidates efficiently. The webcast will be available on their website and archived for later access.
EQRx and Absci Corporation (ABSI) have entered a discovery collaboration to develop affordable, innovative therapeutics utilizing Absci's Drug Creation™ technology. This partnership aims to produce several clinical candidates, particularly in oncology and immunology. The collaboration is designed to enhance EQRx's portfolio with cost-effective treatment options while Absci may invest further at various development stages for a larger share of sales. This aligns with EQRx's mission to provide new medicines at lower prices.
Absci Corporation has formed a strategic collaboration with EQRx to enhance its portfolio of affordable medicines. This partnership will leverage Absci's Drug Creation™ technology alongside EQRx's clinical development capabilities to engineer multiple protein-based therapeutics targeting oncology and immunology. Absci may invest further at various development stages for a larger share of product sales. The collaboration aims to accelerate the discovery and production of innovative treatments, thus making a significant impact on patient care.
Absci Corporation (Nasdaq: ABSI) announced its participation in the BofA Securities 2021 Tech Solutions for Drug Discovery Conference. The virtual presentation is scheduled for September 20 at 2:00 p.m. PT / 5:00 p.m. ET. Attendees can access the live and archived webcast on Absci's website.
Absci utilizes deep learning and synthetic biology to enhance protein therapeutic potential through its Integrated Drug Creation™ Platform, aimed at discovering drug targets and optimal biotherapeutics efficiently.
Absci Corporation (Nasdaq: ABSI) reported its financial results for Q2 2021, showing a revenue of $0.7 million, up from $0.6 million in Q2 2020. The company recorded a significant net loss of $41.2 million, driven by increased R&D expenses of $11.0 million and SG&A expenses of $5.2 million. Key highlights include the acquisition of Totient, the completion of an IPO raising approximately $210 million, and the expansion of its workforce by over 100 employees. Absci also signed key agreements with PhaseBio and Alpha Cancer Technologies to advance its Integrated Drug Creation™ Platform.
Absci Corporation announced the closing of its initial public offering (IPO) on July 26, 2021, raising $230 million by selling 14,375,000 shares of common stock at $16.00 per share. The offering included full exercise of the underwriters' option for an additional 1,875,000 shares. Absci's stock began trading on the Nasdaq Global Select Market under the ticker symbol ABSI on July 22, 2021. Leading underwriters included J.P. Morgan, Credit Suisse, and BofA Securities.
Absci Corporation has announced the pricing of its initial public offering (IPO) of 12,500,000 shares at a price of $16.00 per share. The offering is expected to generate gross proceeds of $200.0 million, not including underwriters' options. Trading on the Nasdaq under the ticker symbol ABSI begins on July 22, 2021, with the offering closing anticipated on July 26, 2021, pending customary conditions. Notable managers for this IPO include J.P. Morgan, Credit Suisse, and others.
Absci Corporation has filed a registration statement on Form S-1 with the SEC for a proposed initial public offering (IPO) of its common stock. The number of shares and price range are yet to be determined. Absci aims to list its stock on The Nasdaq Global Market under the symbol ABSI. Joint book running managers for the offering include J.P. Morgan, Credit Suisse, BofA Securities, Cowen, and Stifel. This filing does not constitute an offer to sell securities prior to registration.